AU2020298246A1 - Compounds for inhibiting FGFR4 - Google Patents

Compounds for inhibiting FGFR4 Download PDF

Info

Publication number
AU2020298246A1
AU2020298246A1 AU2020298246A AU2020298246A AU2020298246A1 AU 2020298246 A1 AU2020298246 A1 AU 2020298246A1 AU 2020298246 A AU2020298246 A AU 2020298246A AU 2020298246 A AU2020298246 A AU 2020298246A AU 2020298246 A1 AU2020298246 A1 AU 2020298246A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
group
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020298246A
Other languages
English (en)
Inventor
F. Anthony Romero
Yingzi XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of AU2020298246A1 publication Critical patent/AU2020298246A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020298246A 2019-06-21 2020-06-18 Compounds for inhibiting FGFR4 Abandoned AU2020298246A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864883P 2019-06-21 2019-06-21
US62/864,883 2019-06-21
PCT/US2020/038541 WO2020257527A1 (en) 2019-06-21 2020-06-18 Compounds for inhibiting fgfr4

Publications (1)

Publication Number Publication Date
AU2020298246A1 true AU2020298246A1 (en) 2022-01-27

Family

ID=74037325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020298246A Abandoned AU2020298246A1 (en) 2019-06-21 2020-06-18 Compounds for inhibiting FGFR4

Country Status (7)

Country Link
US (1) US20220362245A1 (enExample)
EP (1) EP3986405A4 (enExample)
JP (1) JP2022537415A (enExample)
CN (1) CN114144176A (enExample)
AU (1) AU2020298246A1 (enExample)
CA (1) CA3144366A1 (enExample)
WO (1) WO2020257527A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003400B (zh) * 2021-10-22 2025-05-02 暨南大学 2-甲酰基四氢萘啶类化合物及其药用组合物和应用
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000115A1 (en) * 2013-10-25 2017-07-05 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
US9802917B2 (en) * 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2017164705A1 (ko) * 2016-03-24 2017-09-28 재단법인 대구경북첨단의료산업진흥재단 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물
CN113105454B (zh) * 2016-05-20 2022-10-11 江苏豪森药业集团有限公司 Fgfr4抑制剂、其制备方法和应用
CN109563091B (zh) * 2016-08-12 2022-04-29 江苏豪森药业集团有限公司 Fgfr4抑制剂及其制备方法和应用
CN108341815A (zh) * 2017-01-25 2018-07-31 上海喆邺生物科技有限公司 一种抑制激酶化合物及其用途
CN109745321B (zh) * 2017-11-08 2022-04-29 上海翰森生物医药科技有限公司 包含fgfr4抑制剂的药物组合物

Also Published As

Publication number Publication date
EP3986405A1 (en) 2022-04-27
EP3986405A4 (en) 2023-06-14
JP2022537415A (ja) 2022-08-25
US20220362245A1 (en) 2022-11-17
WO2020257527A1 (en) 2020-12-24
CN114144176A (zh) 2022-03-04
CA3144366A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
KR20220130168A (ko) 피리미딘-4(3h)-케톤 헤테로시클릭 화합물, 그의 제조 방법, 및 의약 및 약리학에서의 그의 용도
JP2022110080A (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法
KR102204804B1 (ko) 디히드로피라졸 gpr40 조절제
US11203587B2 (en) Thyroid hormone receptor beta agonist compounds
WO2019201283A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN112469720B (zh) 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
JP7357617B2 (ja) 心不全およびそれに関連する障害の治療または予防に有用なβ－３アドレナリン受容体のモジュレーター
WO2023154913A1 (en) Inhibitors of parg
JP2017528475A (ja) Ｒａｆキナーゼ阻害剤としての化合物および組成物
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
JP2026027279A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
AU2020298246A1 (en) Compounds for inhibiting FGFR4
US20250059206A1 (en) Fused ring compound acting as shp2 inhibitor
KR20250164146A (ko) 치환된 설탐 화합물 유도체 및 이의 약제학적 용도
CA3046864C (en) Cdk4/6 inhibitor
CN121816347A (zh) 药物化合物
WO2026075941A1 (en) Pyridazinone derivatives as pad4 inhibitors
CN121426801A (zh) 吡唑并吡啶类化合物及其用途
WO2024158878A1 (en) Fused tetracyclic selective parp1 inhibitors
KR20250170567A (ko) 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도
HK40058867A (en) Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders
HK40058868A (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
BR122024019819A2 (pt) Compostos de aminoácidos, seus usos e composição farmacêutica dos mesmos
CA3046864A1 (en) Cdk4/6 inhibitor

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application